I did my PhD in the department of Computer Science in The Chinese University of Hong Kong from 2003 to 2006. My research project was bidding strategies in agent based continuous double auctions (CDAs). I had been researching on the new bidding strategy and powerful factors which can improve the performance of existing bidding strategies in CDAs. After that, I had worked as PostDoc from 2007 to 2012 in the national research institute of mathematics and computer science (CWI), and later at the department of the Built Environment, TU/e, The Netherlands. In the meanwhile, I had extended my research area from bidding strategies adopted by agents to the auctions mechanisms in centralized systems and distributed systems. Moreover, giving my experience on multi-agent simulation and adaptive agent behaviour, I had been involved in the activity travel scheduling for multiple individuals where joint activity and travel scheduling, credit mechanism, social network, and negotiation have been interwoven into such a dynamic system. Since 2012, I had been working at R&D, Vanderlande Industries. My work focused on a new generation of software product which plans realtime multiple shuttles’ travelling and meets the throughput requirement in the distribution center.
Anouk Suntjens (TU/e supervisor Pieter Van Gorp) won the VMBI-MIM Future Award 2013. Title of the thesis: “Knowledge Translation and Maintenance in health care: Identification of the requirements for tool support”.
More information of the MIC 2013 program
Stan N. Finkelstein, MD (Senior Research Scientist, Massachusetts Institute of Technology, Engineering Systems Division;Associate Professor of Medicine, Harvard Medical School)
Please confirm your attendance by sending an email to email@example.com
Title: Finding New Lives for Old Drugs: Ideas about using a Systematic Approach
Abstract: When drugs are approved by regulatory agencies like the European Medicines Agency and the U.S. Food and Drug Administration to enter the market, they are labeled only for specific therapeutic uses, for which detailed evidence from clinical trials established their safety and efficacy. For many of these drugs, sooner or later, some evidence emerges (or at least a good reason to believe) that they would be efficacious for other uses, often referred to as “off-label uses”. In the U.S., prescribing of medicines for off-label uses, by qualified physicians is perfectly legal, though pharmaceutical companies would be breaking the law if they advertised or promoted them for such unauthorized uses. Such off-label uses are only
occasionally the object of later clinical trials to confirm their therapeutic value.
In this seminar, I will begin by reviewing evidence from a data-based study that examined the proportion of all drug prescribing that is off-label and identified the kinds of medicines that are most often used in this fashion. Then I will share some ideas and plans for new research aimed at systematically identifying medicines whose off-label uses could be evaluated through the conduct of “pseudo-trials,” using matched patient cohorts from electronic medical record databases.
The ultimate objective is to develop convincing evidence of these additional therapeutic uses of older drugs, in order that they can be prescribed more widely, and enable more patients to benefit from them.
Speaker Bio: Stan N. Finkelstein, M.D. is a Senior Research Scientist in the the MIT Engineering Systems Division. He also serves as Associate professor of Medicine at Harvard medical School and is a member of the faculty of the Division of Clinical Informatics at Beth Israel Deaconess Medical Center. He received his Masters of Science and Bachelors of Science degrees in
Chemical Engineering from MIT in 1971, and an M.D. from Harvard Medical School in 1975.
Since 1975, he has worked actively in the field of medical technology assessment and transfer at MIT. He conducts research and teaches classes in the development and evaluation of medical practice and technology and in health economics and policy, both at MIT and Harvard Medical School.
An active consultant to U.S. and international pharmaceutical, biotechnology, and medical device firms, as well as to health services organizations and government agencies; Dr. Finkelstein is an expert in outcomes research. His areas of specialization extend to the business-government interface related to medical technology, especially product development, clinical research design and third-party reimbursement. Dr. Finkelstein is author, editor, or contributor to several books and numerous articles on these subjects.
Dr. Finkelstein’s current research interests include analyses relating to the economics of illness and pharmaceutical treatment and to low probability, high consequence public health events. His publications include studies of cost of illness and cost-effectiveness of treatment. He is co-author of several recent articles that address the link between treatment of illness and productivity at work, and the role of advancing science and technology in changing patterns of medical treatment.
Commissaris Onderwijs Loek Jongen:
“Ms Vanderfeesten, Congratulations! From the way you give your lecturers, students feel that you are highly motivated and passionate about your area of research. You really want to help your students, and during instructions, you give critical, constructive critisism. In your lectures, you combine theory and practice, by for example inviting guest lecturers. Students think you are a nice and pleasant person, easy going, very flexible and approachable. Some give the Industria Business Trip as an example. To sum up: you are passionate, helpful and friendly. Congratulations!”
My name is Harold Lijten.
My colleagues describe me as a weathered professional with a broad and deep knowledge of the finance domain and its intersection with IT. My professional specialization is enterprise- software architecture and software development.
During my daily practices some really interesting questions cross my path and they are the reason for me to maintain a solid link with the academic world.
One of these questions which has my attention for a long time is; can we create capabilities within the architecture of an information system which facilitate a substantial increase of the flexibility and life-time of an information system? My strong desire to answer this question has led to some years of research already.
The purpose of my current research is to determine the contribution of the concept scenario planning applied during the process of designing and developing an information system. The main subject of study is researching the possible implications for the life-time of an information system and its architecture when scenario planning is used during the process of design and development.
Every year, Industria organizes the Education Awards ceremony. Awards will be handed out to the best lecturers of 2012-2013 in four categories: Propedeuse (First year Bachelor), Post-propedeuse (second and third year Bachelor), Innovation Management and Operations Management and Logistics.
Irene Vanderfeesten and Pieter Van Gorp are amongst the nominees! Irene is nominated for Post propedeuse as well as Operations Management and Logistics. Pieter is nominated for Post propedeuse.
Industria Education Awards 2013
31 October 2013; The drink starts at 16.00h, and the official ceremony starts at 17.00h.
The Villa, Eindhoven
The Information Systems group congratulate the new board of Industria with their constitution.
I am graduated from Industrial Engineering Department from Middle East Technical University in 2009. I completed my MSc degree in 2011 there while working as a teaching assistant. I have assisted courses such as simulation, systems thinking, network flow, work systems analysis and design, data mining and so on.
I focused on data mining and multi criteria optimization during my masters studies. For my thesis, I developed a distance-based multi-criteria optimization algorithm for the sorting problem.
I was involved in an applied project in KU Leuven last year about process improvement in the emergency department of Turnhout Hospital. We developed an advanced simulation model of the department based on the real data provided by the hospital. What-if analysis is conducted for evaluating the performance of different schedules. The project continues with integration of a genetic algorithm for staff schedules with the simulation model.
A bioinformatic approach to mesothelioma therapeutics: from ADAM to TRAP
Arginine deprivation is a novel antimetabolite strategy for the treatment of arginine-dependent cancers that exploits differential expression and regulation of key urea cycle enzymes. Several studies have focused on inactivation of argininosuccinate synthetase 1 (ASS1) in a range of malignancies, including melanoma, hepatocellular carcinoma, and mesothelioma. Promoter methylation, in particular, has been identified as a mechanism for loss of the tumor suppressor role of ASS1 leading to tumoral dependence on exogenous arginine. Clinical trials of several arginine depletors are ongoing, including pegylated arginine deiminase (ADI-PEG20, Polaris Group, US) and bioengineered forms of human arginase. The challenge will be to identify tumors sensitive to arginine depletors, and integrate these agents into multimodality drug regimens using predictive biomarkers. Here, we have applied a bioinformatic approach to identify tractable pathways with ADI-PEG20 in the treatment of patients with mesothelioma. Recently, our phase 2 study of ADI-PEG20 in mesothelioma (ADAM) completed accrual and we are now launching a phase I combinatorial trial (TRAP) in the UK based on our bioinformatics studies.
Dr Peter Szlosarek (MBBS BSc MRCP PhD) is a Clinical Senior Lecturer at the Barts Cancer Institute, and Cancer Physician at St. Bartholomew’s Hospital, London. He studied Medicine and Pharmacology at King’s College, London and then specialised in Medical Oncology completing a PhD on the links between TNF-a, inflammation and cancer at the University of London. His clinical and lab research interests are in metabolic approaches to cancer therapy, particularly the role of arginine deprivation therapy in arginine-dependent cancers. This has led to clinical trials of the arginine-depleting agent ADI-PEG20 (Polaris Group, US) in mesothelioma (CTAAC grant) and small cell lung cancer, the latter a collaboration with the Ludwig Institute for Cancer Research in New York, US. He is funded by several grant bodies including Cancer Research UK, Barts and The London Charity, Medical Research Council and the British Lung Foundation. He maintains a research-orientated clinical practice at Barts in thoracic and cutaneous malignancy and is a member of the Royal College of Physicians, the Association of Cancer Physicians, the EORTC, AACR and ASCO.
Regulatory Compliance Management (RCM) is widely recognized as one of the main challenges still to be efficiently dealt with in Enterprise Models (EMs). In the discipline of Business Process Management (BPM) in particular, which plays a central role in modern management of enterprises, compliance is considered as an important driver of the efficiency, reliability and market value of companies. It consists of ensuring that enterprise systems behave according to some guidance provided in the form of regulations.
Existing approaches to RCM tackle this issue from two different perspectives: methodological and formal. The first category of a approaches is widely used in the industry and proposes several processes based on controls for compliance audit and governance. The second category of approaches seeks to construct complex formal languages and reasoning engines for automatically deciding on the state of compliance of a business process, but remains hardly accessible to practitioners who are not trained in formal methods. This work provides an approach for modeling and checking of regulatory compliance that profits from the power of complex formal languages and is specifically targeted at practitioners.
For this purpose, we introduce CoReL, a visual domain-specific modeling language for representing compliance requirements. The main objective behind CoReL is to bring the task of compliance modeling to the business user level where it belongs. CoReL allows to leverage business process compliance modeling and checking, enhancing it with regard to, user-friendliness and coverage of various enterprise artifacts, as well as multiple types of regulatory constraints. Both informal and formal semantics of CoReL are introduced and its use for modeling and checking compliance regulations is shown on an example.
Dr. El Kharbili’s core fields of research are Enterprise Architectures/Business Process Management and Model Driven Engineering. His main area of research covers the development of procedures, languages and tools for the modelling, automated verification and analysis of regulatory compliance in information systems as well as the governance thereof.
Dr. El Kharbili is a graduate both the Grenoble Institute of Technology (France) and the Karlsruhe Institute of Technology (Germany), and holds a M.Sc. from each university. He holds a Ph.D. in computer science from the University of Luxembourg and another Ph.D. degree also in computer science from the University of Osnabrueck (Germany). In his Ph.D. thesis he developed methods and languages for enterprise regulatory compliance management of enterprise models and business processes by applying and extending techniques form formal methods, security policies and software language engineering.
Prior to that he worked in the software industry and industrial research at both the IDS Scheer AG (inventors of the ARIS framework) and SAP AG. Dr. El Kharbili’s core fields of research are Enterprise Architectures/Business Process Management and Model Driven Engineering.
If you would like to know more, you can find a more complete BIO on: http://theintelligententerprise.blogspot.com.au/2010/11/bio.html